vs
Side-by-side financial comparison of Navios Maritime Partners L.P. (NMM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Navios Maritime Partners L.P. is the larger business by last-quarter revenue ($327.6M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Navios Maritime Partners L.P. runs the higher net margin — 21.4% vs 1.6%, a 19.7% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -4.3%).
Navios Maritime Holdings Inc. is a multinational, vertically integrated seaborne shipping and logistics company focused on the transport and transshipment of drybulk commodities including iron ore, coal and grain.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NMM vs PCRX — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $327.6M | $177.4M |
| Net Profit | $69.9M | $2.9M |
| Gross Margin | 90.5% | — |
| Operating Margin | — | 3.9% |
| Net Margin | 21.4% | 1.6% |
| Revenue YoY | -4.3% | 5.0% |
| Net Profit YoY | -31.1% | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $327.6M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | — | $168.6M | ||
| Q2 24 | $342.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $69.9M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-143.5M | ||
| Q2 24 | $101.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | 90.5% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | 88.3% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | 21.4% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | 29.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $377.0M | $144.3M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | — | $653.9M |
| Total Assets | $5.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | $377.0M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | $272.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | $2.0B | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | — | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | — | $749.6M | ||
| Q2 24 | — | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $5.9B | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $5.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NMM
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
